Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

vudalimab

Phase 2Monoclonal antibody

vudalimab is one of 26 biologic programs targeting Malignancies. It is currently in Phase 2.

1

Indications

4

Total Trials

1

Active Trials

25

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesActive, not recruiting

MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Malignancies

#DrugCompanyPhaseTrials

Fludara

Opdivo

Bristol-Myers Squibb

Cellcept

Eloxatin

Prograf

VVeloxis Pharmaceuticals

Fluoropyrimidine

Gemzar

Johnson & Johnson

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Tibsovo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Terminated·EEmory University·Phase 1·NCT05733351·4 enrolled

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·XXencor, Inc.·Phase 2·NCT05005728·72 enrolled

Malignancies1 trial

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Active, not recruiting·XXencor, Inc.·Phase 2·NCT05032040·170 enrolled

Locally Advanced Thyroid Gland Anaplastic Carcinoma1 trial

A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer

Suspended·NNorthwestern University·Phase 2·NCT05453799·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for vudalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vudalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vudalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: XXencor, Inc.

Related News